Work

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma

Year: 2016

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-16-2395

Authors: Martin H. Voss, Rupal S. Bhatt, Elizabeth R. Plimack, Brian I. Rini, Robert S. Alter, J. Thaddeus Beck, Dawn Wilson, Xiaosha Zhang, Musa Mutyaba, Chad Glasser, Kenneth M. Attie, Matthew L. Sherman, Shuchi S. Pandya, Michael B. Atkins

Institutions: Memorial Sloan Kettering Cancer Center, Cornell University, Weill Cornell Medicine, Beth Israel Deaconess Medical Center, Fox Chase Cancer Center, Cleveland Clinic, Hackensack University Medical Center, Highlands Oncology Group, Acceleron Pharma (United States), Georgetown University Medical Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W2562875191

FWCI: 3.705

Cites: 47

Cited by: 29

Related to: 10